At Parthenon Therapeutics, we are reprogramming the tumor microenvironment to beat cancers
Breaking Barriers
To Better Cancer Treatment
Many Cancer Patients Don't Benefit from Existing Therapies – We Lead the Next Generation of Treatment
As our understanding of the mechanisms of cancer resistance has grown, so too have our strategies to combat/address those biological challenges. However, despite recent advances in anti-cancer therapy, many people living with cancer continue to have low response and poor prognosis. Parthenon's approach is informed by our improved understanding of the important role of the tumor microenvironment in fighting disease.
our team
ABOUT our team
We are scientists, drug developers, clinicians, pathologists, bioinformaticians, engineers, innovators, and cancer warriors redefining the treatment landscape for patients with recalcitrant cancers.
Laurent is co-founder, CEO & Chairman of Parthenon Therapeutics.
He has contributed to the identification and development of seven novel medicines (Xeljanz®, Hemangiol®, Javlor®, Renflexis®, Brenzys®, Ontruzant®, Hadlima® – biologics and small molecules) addressing unmet medical need across multiple disease areas that generate > $3B in annual sales.

Laurent has also led business and R&D functions in both pharma and biotech (US and EU), including CEO of Kymera Therapeutics, head of R&D with Pierre Fabre Pharmaceuticals, and positions of increasing leadership responsibilities on the business and science fronts at Pfizer, Merck, and Pieris contributing to the advancement of 21 drug candidates into clinical development across multiple disease areas and modalities. He has completed partnering transactions worth over $3B in biobucks and raised > $250M.

He studied chemistry and pharmacology (Ph.D.) at Vanderbilt University and completed postdoctoral training at UNC/Chapel Hill and Duke University where he was the recipient of an American Heart Association Fellowship. He has co-authored over 70 papers and patents. Laurent also serves as an independent director on the board of Cytovia, Ixaka, Ermium, and is a member of Ventus' scientific advisory board.
Olga is a co-founder and Chief Operating Officer of Parthenon Therapeutics, bringing 25 years of diverse pharma/biotech experience spanning the entire value chain from R&D to Commercial Launch, business development, strategy, fundraising, licensing, and M&A transaction expertise gained through her experience at top tier pharmaceutical and biotech companies (PFIZER, BMS, MERCK & CO.).

Over the course of her career, Olga has led teams to deliver 20 different clinical candidates, 3 drug launches, and multi-year/multi-million dollar deals (sell and buy side). As Vice President, Business Development at Evotec, Olga leads partnering for cell therapy and rare monogenic CNS disorders.

In addition, Olga is co-founder and president of Brighter Ventures, a nonprofit organization advancing women-led entrepreneurship, and she serves on the board of a pediatric oncology nonprofit organization, Coucou Nous Voilou.

Olga received her B.S. in Pharmaceutical Sciences from SUNY at Buffalo and TRIUM Global MBA from the NYU Stern School of Business, HEC Paris, and the London School of Economics.
Laura Dillon is the Head of Translational Biomarkers, responsible for designing and implementing Parthenon's biomarker strategy. She has over 15 years of experience in industry, academia, and government. Prior to joining Parthenon, Laura was the Director of Pathology Data Strategy at AstraZeneca, focusing on the development of novel methodologies to extract information from imaging datasets and the implementation of non-invasive bioimaging techniques to advance the drug development pipeline. Laura has a Ph.D. in Bioinformatics and Genomics from the University of Maryland.
Glenn is a co-founder and Head of Discovery of Parthenon Therapeutics. Glenn is a hematologist/medical oncologist with over 20 years of clinical practice and drug development experience.

Prior to Parthenon, he's held positions of increasing scientific leadership responsibilities across the biotech industry (CEO of BioCurate, CSO of Xilio and TetraLogic, and NED at Oxford Biotherapeutics).

From 2002-2012, he was VP and Global Head of Hematology/Oncology Research at Amgen, California, responsible for 5 research sites; for supporting marketed products including the filgrastim and erythropoietin franchises (approx. US$4B pa and US$8B pa respectively). Over 25 clinical-stage molecules emerged from his group.

Glenn has highlighted the issue of research integrity and scientific reproducibility. He has made presentations on this subject including to President Obama's Science Council, the White House, US National Institutes of Health, US Academies of Science, US National Institute of Standards and Technology, Wellcome Trust, NHMRC, and numerous Universities, Research Institutes and companies.

His early research first described human G-CSF, then demonstrated that G-CSF-"mobilized" blood stem cells (so called "stem cell transplantation") hastened recovery versus bone marrow transplantation.

He was elected as the first Foreign Fellow to the American Society of Clinical Investigation (2000), the Association of American Physicians (2008), to the Research "Hall of Fame" at his alma mater, the Royal Melbourne Hospital (2014), to the Australian Academy of Health and Medical Sciences (2014). He has published over 200 papers (~25,000 citations; h-index 77; i10-index 188, source Google Scholar, August 2020). His TED-x seminar "The Complex Biology of Cancer" has >100,000 views.
Sidney Sponer is a BASc and MA (Quest University Canada, Wilfrid Laurier University) graduate who has joined the Parthenon team to support Operations. Although she studied English and Film, she is passionate about healthcare and the possibilities of developing cutting edge technology for patients to receive better care. She also serves as a Board Member and Secretary of the Collaborative Vision Foundation which funds Trachoma surgeries and conducts ophthalmology research in Egypt.
Travis is a co-founder and Chief Medical Officer of Parthenon Therapeutics. Travis is a practicing surgical oncologist and clinical trialist with over 13 years of oncology drug development and clinical practice experience.

He received a BS in Chemistry from the United States Military Academy at West Point and a medical degree from Vanderbilt University Medical School. He completed General Surgery residency at BAMC and Complex General Surgical Oncology fellowship at University of Texas MD Anderson Cancer Center. He has deployed multiple times overseas to combat zones and within the US for COVID-19 response with the US Army. He has 13 years of experience in translational cancer immunotherapy research with intimate experience with the design, initiation, and execution of cancer immunotherapy clinical trials. He has over 60 peer-reviewed oncology publications, over 120 published abstracts, and multiple book chapters.
SCIENTIFIC ADVISORY BOARD
ADVISORY BOARD
BOARD OF DIRECTORS
Board of Directors
Our Investors
Our INVESTORS
Join the Fight
Join the Fight
Our team is always excited to talk about collaborations to bend the survival curve for patients.
Join the Fight
Join the Fight
Our team is always excited to talk about collaborations to bend the survival curve for patients.
© All rights reserved
One Broadway
Cambridge, MA 02142